NMD treats A to Z

The broad applicability of NMD Pharma ApS’s approach to treating neuromuscular conditions persuaded INKEF Capital to lead the company’s tranched €38 million ($46.6 million) series A round.

Fellow new investor Roche Venture Fund and existing investors Lundbeckfonden Emerge and Novo Seed also participated. ...